Slides
Page 1
Power and precision in cancer radiotherapeutics NASDAQ: PSTV Corporate Update January 2026
Page 2
Plus Therapeutics, Inc. NASDAQ: PSTV Cautionary Note Regarding Forward Looking Statements 2 This presentation contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this presentation other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “potential,” “anticipating,” “planning”, “projecting”, “expecting” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of REY OBIQ including the ability of REYOBIQ to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets, which include the Company’s nanomedicine platform and commercializing CNSide, REYOBIQ and 188RNL-BAM; the Company’s manufacturing capabilities and commercial scalability of the Company’s product candidates; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT -GBM, ReSPECT -LM and ReSPECT -PBC clinical trials; possible negative effects of REYOBIQ ; the continued evaluation of REYOBIQ , including through evaluations in additional patient cohorts; the intended functions of the Company’s platform and expected benefits from such functions; development and utility of the CNSide leptomeningeal metastases diagnostic test; and upcoming catalysts and cash runway. The forward-looking statements included in this presentation could differ materially from those expressed or implied by these forward-looking statements because of risks, uncertainties, and other factors that include, but are not limited to, the following: the early stage of the Company’s product candidates and therapies; the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash; to fund its operations in the near-term and long-term, on terms acceptable to us or at all; the outcome of the Company’s partnering/licensing efforts; risks associated with laws or regulatory requirements applicable to the Company, including the ability to come into compliance with The Nasdaq Capital Market listing requirements; market conditions; product performance; litigation or potential litigation; and competition within the cancer diagnostics and therapeutics field; ability to develop and protect proprietary intellectual property or obtain licenses to intellectual property developed by others on commercially reasonable and competitive terms; manufacturing supply chain risks; and material security breach or cybersecurity attack affecting the Company’s operations or property. This list of risks, uncertainties, and other factors is not complete. Plus Therapeutics discusses some of these matters more fully, as well as certain risk factors that could affect Plus Therapeutics’ business, financial condition, results of operations, and prospects, in its reports filed with the SEC, including Plus Therapeutics’ annual report on Form 10-K for the fiscal year ended December 31, 2024, quarterly reports on Form 10-Q, and current reports on Form 8-K. These filings are available for review through the SEC’s website at www.sec.gov. Any or all forward-looking statements Plus Therapeutics makes may turn out to be wrong and can be affected by inaccurate assumptions Plus Therapeutics might make or by known or unknown risks, uncertainties, and other factors, including those identified in this presentation. Accordingly, you should not place undue reliance on the forward-looking statements made in this presentation, which speak only as of its date. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Page 3
Executive Summary Contact us at investor@plustherapeutics.com
Page 4
Plus Therapeutics, Inc. NASDAQ: PSTV Plus Therapeutics (PSTV) Overview 4 Glossary: rGBM – recurrent glioblastoma Dx – diagnostic TAM – total addressable market CTC – circulating tumor cells LM – leptomeningeal metastases mets – metastases BBB – blood brain barrier CSF – cerebral spinal fluid PBC – pediatric brain cancer mOS – median overall survival MTD – maximum tolerated dose Tx – radiotherapeutics CNS – central nervous system SOC – standard of care Best-In-Class Diagnostic for CNS Mets - CNSide®: >$6B TAM + U.S. commercial relaunch Q3 2025 – Projected 500K patients / year + Announced first of planned national coverage agreements, with UnitedHealthcare and Humana + Previously commercialized, ordered by 120 U.S. institutions + Data and analytics for personalized therapeutic approach and predictive models Multiple Mid-Stage ReSPECT Clinical Trials of REYOBIQ + First-in-class drug treating leptomeningeal mets (LM), Dosing/Phase 2 trial enrolling + Completing recurrent glioblastoma (rGBM) Phase 2 trial in 2025 First-In-Class Radiotherapeutic for CNS Cancers: >$16B TAM + Safe, precision therapy with up to 20x radiation delivery vs. standard of care + FDA Fast Track & Orphan Designations facilitate expeditious approval process
Page 5
Company Overview Contact us at investor@plustherapeutics.com
Page 6
Plus Therapeutics, Inc. NASDAQ: PSTV Epidemic of Central Nervous System Cancers 6 Growing mets epidemic dwarfs incidence of primary brain cancers 10:1 ratio Up to 30% of adult cancer patients will develop CNS mets1 Over 1 million patients at risk of CNS mets in U.S.1 >1M Epidemic due to improved outcomes for primary cancer treatments (breast, lung, melanoma, etc.) 1. Boire A. Metastasis to the Central Nervous System. Continuum (Minneap Minn). 20 20 Dec;26(6):1584 -1601 .doi: 10.121 2/CON.000000 000000 0939. PMID: 33 273173 ; PMCID: PM C992 4436.
Page 7
Plus Therapeutics, Inc. NASDAQ: PSTV CNS Cancer Survival Rate- Little Progress Over 40 Years 7 The 4 decade-old CNS cancer ‘playbook’ has not worked 0 20 40 60 80 100 120 1980 1985 1990 1995 2000 2005 2010 2015 2020 Median Overall Survival (Months) CNS Cancers Non-CNS Cancers CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors D iagnose d in the United State s in 2015 -2019 . Neuro Oncol. 202 2 Oct5;24(Suppl 5):v1 -v95. doi: 10.109 3/ne uonc/noac202. PM ID: 3619 6752; PMCI D: PMC9533 228.
Page 8
Plus Therapeutics, Inc. NASDAQ: PSTV Limitations to Gains in CNS Cancer Survival 8 The unique nature of the CNS creates both diagnostic & therapeutic challenges Pharmaceuticals Only 2% of drugs can cross BBB Genetic drift common in mets External Radiation Proven MOA, dosing limited Surgery If operative, clean tumor margins unobtainable Poor Diagnostic Options Leptomeningeal Mets: 2-4x underdiagnosed1 Standard diagnostic Cytology from 19042 Better imaging has not been the answer 1. Le Rhun E, et al. – Le ptomeninge almetastasis : a RANO proposalLancet Oncology , 2017 2. Dufour , H. J Bras Patol Med Lab 57 , 5–13 (2021 )
Page 9
Plus Therapeutics, Inc. NASDAQ: PSTV Roadmap to Improve CNS Cancer Survival 9 Plus is creating a new playbook ✔ Improved Diagnostic – CNSide Dx Platform ➢ Better Biomarkers / Concrete Outcomes Measures – CSF circulating tumor cells ✔ Improved Therapeutic – REYOBIQ targeted radiotherapeutic ➢ Reduce / Remove Impact of the BBB - Innovative Drug Delivery ✔ Unified Advanced Data Analytics – Dx & Tx Improvements + Partnerships
Page 10
Plus Therapeutics, Inc. NASDAQ: PSTV Plus’ Playbook to Improve Survival in CNS Cancers 10 Focused ‘Roche’ model for CNS oncology Improved survivals in LM CNSide Diagnostics + Launched in late 2025 + Nearing 100m covered lives + $6B opportunity* Lead drug REYOBIQ Unified data analytics platform + Up to 20x radiation delivery + Bypass BBB + No MTD reached in multiple clinicals + $16B opportunity* + CNSide cellular and molecular data + REYOBIQ imaging & delivery data + Pipeline development + Further OS gains DataAnalytics ClinicalImpact Fully Integrated CNS Platform + CNSide: est. 50% inc. in OS + REYOBIQ: est. additional 50% inc. in OS * Refe r to slide 14
Page 11
Plus Therapeutics, Inc. NASDAQ: PSTV LM Epidemiology & Standard Care Pathway 11 Near term path to doubling survival in LM + US LM Diagnoses ~ 125,000/year1 + Underdiagnosed: LM cases are 2-4x more common based on autopsy findings2 + Poor survival: 4-6 weeks without treatment vs. 4-6 months with treatment3 + Primary Solid Cancers: ~ 80% of cases due to breast & lung CA and Melanoma4 ~Half receive palliative care, hospice5 mOS ~ 5 weeks ~Half receive Tx mOS ~ 5 months Blended mOS ~ 3 months 6 Increase to 90% receive Tx 7 Blended mOS ~ 4.5 months 50% of Tx receive REYOBIQ 7 Blended mOS ~ 7 months + CNSide Standard of Care + REYOBIQ PLUS 1. Nayar G, et al. Le ptomeninge al disease : curre nt diagnostic and therapeutic strate gie s. Nature Reviews Clinical Oncology. 2017 .DOI: 10 .1038/ nrclinonc.2017. 128 2. Le Rhun E, et al. – Le ptomeninge al metastasis: a RANO proposal Lance t Oncology, 201 7 3. Boire A. Metastasis to the Central Nervous System. Continuum (Minneap Minn). 202 0 Dec; 26(6): 1584 -1601 . doi: 1 0.1212/ CON.00 0000000000 0939. PMID: 33 273173 ; PMCID: PM C992 4436 4. J Exp M ed (2024) 221 (4): e20212 121. https :// doi.org/ 10.10 84/jem.2021 2121 5. Gensler, R., Xia, Y., Horowitz, M.A. et al. Outcomes of leptome ningeal disease after only vertebral osseous me tastases: a real -world analysis using the TriNetX database. J Neurooncol 175, 2 19–229 (202 5). https:// doi.org/10.10 07/s11060-025-0512 2-w 6. Batool A, Kasi A. Le ptomeninge al Carcinomatosis. [Update d 2023 M ar 2 7]. In: StatP earls [I nternet]. Treasure I sland (FL): StatPe arls Publishing; 2025 Jan -. Available from: https:/ /www.ncbi.nlm.nih.gov/books/NBK4 99862/ ?referre r= grok.com 7. Manage ment e stimates
Page 12
Plus Therapeutics, Inc. NASDAQ: PSTV TAM for CNSide & REYOBIQ in CNS Mets 12 Initial focus on Leptomeningeal Mets with significant growth potential in Brain Mets $6B+ U.S. Total Addressable Market* 500K+ Total CNS Mets Patients* 1,2,3,4,5 *Notes: • 500K+ CNS mets patients include incidence, at risk, and prevalence populations (base case estimate) • $6B TAM assumes 4.3 tests/patie nt at ~ $3,000 list price (base case estimate on # of tests and pricing) • $16B TAM assumes 56,250 (50% of 90% of the current US LM diagnoses) LM patients receiving 3 REYOBIQ dos es @ $100,00 0 per dose 1. Cagney, D.N. , et al. Neuro Oncol 19(11), 1511 –1521 (20 17). https ://doi.org/ 10.109 3/ne uonc/nox077 2. Groves , M.D. Neuros urg Clin N Am 22, 6 7–78 (2011 ). https ://doi.org/ 10.101 6/j.ne c.201 0.08.00 6 3. Lamba, N., et al. Neuro Oncol 23 (9), 1447 –1456 (20 21). https://doi.org/ 10.109 3/ne uonc/noab10 1 4. Le Rhun, E., et al. Surg Neurol Int 4, 265 (201 3). https://doi.org/ 10.410 3/215 2-7806 .11130 4 5. Nguyen, A., et al. Curr Oncol 30(6), 5906 –5931 (20 23). https ://doi.org/ 10.339 0/curroncol300 60442 $16B+ U.S. Total Addressable Market* 56,250 REYOBIQ Patients *
Page 13
Plus Therapeutics, Inc. NASDAQ: PSTV 2026 Milestones 13 + Reach > 150 million covered lives for CNSide Diagnostic platform + Obtain Medicare and Medicaid coverage + Establish prior commercial order rate (1,250 TCE tests per annum) + Establish 50 or more unique ordering physician customer base for CNSide + Expand platform and launch additional CSF tumor characterization tests * These state me nt s a nd figure s a re targe ts for 202 6 a nd ar e not pr oje ctions and should not be rel ied upon as such. Fur the r, t hes e targe ts are subject to occurre nce s that ma y nega tivel y impa ct our business and our industry g enera lly, whi ch may be out of our control, and which may impact our ability to achieve thes e ta rge ts. + Complete enrollment in ReSPECT-GBM Phase 2 trial for recurrent glioblastoma and conduct end of phase meeting to align on pivotal trial design + Define optimal dose/interval for REYOBIQ in ReSPECT-LM Phase 2 expansion trial and begin enrollment + Complete manufacturing scale-up for REYOBIQ commercial and approval trial supply + Enroll first patient in the ReSPECT-PBC pediatric brain cancer Phase 1 trial with REYOBIQ Diagnostic Therapeutic
Page 14
Plus Therapeutics, Inc. NASDAQ: PSTV Executive Management Team 14 Marc H. Hedrick, MD MBA President & CEO, Plus Therapeutics 30+ years of clinical development and business leadership Andrew Sims, CPA CFO & VP of Finance 25+ years of Financial Leadership Russell Bradley President & General Manager (CNSide) 30+ years of diagnostic & life sciences leadership Russ Havranek, MS MBA Executive VP Corporate Strategy & Business Development 25+ years of development & commercialization experience Andrew Brenner, MD PhD Interim CMO Professor of Medicine and Neuro-Oncology Clinical Investigator Endowed Chair, Mays Cancer Center, UT Health San Antonio
Page 15
Diagnostics Contact us at investor@plustherapeutics.com
Page 16
Plus Therapeutics, Inc. NASDAQ: PSTV Poor Diagnosis Standards in CNS Mets 16 + Cytology: not quantitative, ~ 50% sensitive, no FDA support an as endpoint2 + Imaging: not quantitative, ~75% specific, no FDA support an as endpoint2 + Neither tool helps disease monitoring or treatment selection + Therefore ‘therapeutic nihilism' is common and hospice referrals high The current standard for LM diagnosis (cytology) introduced in 19041 1. DUFOUR, M. H.: M énigite sarcomateuse diffuse avec encahissement de la moe lle e t des racines: Cytologie positive e t s péciale d u liquide cé phalorachidiien. Rev. Neurol. 12: 1 04–106, 1 904 2. Batool A, Kasi A. Le ptomeninge al Carcinomatosis. [Update d 2023 M ar 2 7]. In: StatPearls [Internet]. Treasure Island (FL): StatP earls Publishing; 2025 Jan-..
Page 17
Plus Therapeutics, Inc. NASDAQ: PSTV A Comprehensive CNS Diagnostic Solution 17 Proprietary & highly sensitive tumor cell capture & interrogation system optimized for CNS mets 1. Sweed, N., e t al. Arch Pathol Lab Med (2025 ) 149 (3): 242–252. https ://doi.org/ 10.585 8/arpa.2 023-0295-OA 2. Manage ment estimates 3. Historical Commercial D ata 92% Clinical sensitivity 1 1 cell/5mL Tumor cell detection 2 4 day Sample Stability 2 95% Clinical specificity 1 1 Platform / 4 Tests >$300M Invested in core technology >11,000 Tests completed 3 0 to 25,000+ Tumor cell count range 2 1 ‘Stop Shop’ testing platform
Page 18
Plus Therapeutics, Inc. NASDAQ: PSTV Platform with 4 Tests from a Single Sample 18 Cancer Patient Presents Signs & Symptoms Suggestive of LM Tests Performed & Info Gathered • SoC & CNSide TCE+FISH+ICC+NGS • Tumor cell count & biomarker detection LM Patient Follow-Up Visit Tests Performed & Info Gathered • SoC & CNSide TCE+FISH+ICC • Tumor cell count & biomarker detection Clinical Decision Making • Diagnosis (LM: + or –) based on TCE • LM treatment based on FISH, ICC, NGS Clinical Decision Making • LM treatment based on TCE, FISH, ICC • Continue/Discontinue LM therapy • Use different LM therapy CNSide® CSF Tumor Cell Enumeration (TCE) Detects LM tumor cells in CSF; quantifies LM tumor cells for diagnosis & treatment monitoring CNSide® CSF Fluorescence In Situ Hybridization (FISH) Identifies gene expression abnormalities using fluorescent probes; used by physicians to personalize therapy selection CNSide® CSF Immunocytochemistry (ICC) Confirms origin of tumor cells & identifies gene expression abnormalities CNSide® CSF Next-Generation Sequencing (NGS) Detects clinically relevant mutations in DNA & RNA
Page 19
Plus Therapeutics, Inc. NASDAQ: PSTV CNSide Dx Platform: Products & Services 19 Hospital / Clinic CNSide Lab Shipment DNA Isolation Microfluidic Chip / Channel Tumor Cell Isolation (TCE Cocktail)CEE-Sure® Tube NGS TCI Probe Cocktail A B C Lumbar Puncture / Ommaya Reservoir Proprietary Tech Manufactured In -house (Product): 1. CEE-Sure Tube • Preserves collected CSF specimen (LP/OR) 2. Microfluidic Chip • Cell capture for tumor cell enumeration 3. Cell Interrogation Probe Cocktail • Cell capture for tumor cell interrogation Data Reports w/ Pathologist Interpretation (Service): A. Tumor Cell Enumeration (TCE) • Quantifies tumor cell count B. Tumor Cell Interrogation (TCI) • Identifies gene expression / guides treatment C. Cell Free DNA Analytics (CF -DNA) • Detected clinically relevant mutations Provides a unique & clinically actionable dataset for providers
Page 20
Plus Therapeutics, Inc. NASDAQ: PSTV A Derisked Commercial Opportunity 20 2025 commercial relaunch: clinically proven, market traction, & positioned for scale + Proven high throughput & scalable technology • ~$300M investment in core tech made by original developer • 9 peer-reviewed studies and publications • Clinically validated (FORESEE trial completed) • CSF CTCs in NCCN guidelines* + CNSide commercially available since 2020 by original developer (paused 2023) • Previously launched & accepted by CMS in 2020 • 11,000+ tests ordered • 200+ unique physician users across 120+ institutions • Avg. 4.3 tests/patient + 1st national policy coverages: United Healthcare and Humana • 51 million covered lives with United Healthcare • 16 million covered lives with Humana *Jl Clin Oncology, vol 42,No. 16 suppl, Jume 2024
Page 21
Plus Therapeutics, Inc. NASDAQ: PSTV CNSide Commercial Expansion Plans 21 Commercial & operational foundation now in place for growth in 2026 and beyond 2025- Established core commercial & operational capabilities • CLIA certification and broad state licensure • Commercial operations team and IT infrastructure • Expand testing operations footprint near Texas Medical Center • Market access and payor agreements • Offering via early access program and select academic sites 2026- Commercial scale-up phase • Expand sales team and related functions for national coverage • Increase covered lives via private & public payor agreements • Improve test automation and expand product offerings • Focus on neuro-oncology community 2027- Growth phase • Broaden commercial reach to medical oncologists, private hospitals and clinics • OUS expansion 2026 2027
Page 22
Targeted Radiotherapeutics Contact us at investor@plustherapeutics.com
Page 23
Plus Therapeutics, Inc. NASDAQ: PSTV A First-In-Class Targeted Radiotherapeutic 23 3 Part Drug Formulation Therapeutic Impact 186Re BMEDA 100 nm NanoLiposome Radioisotope, Small Molecule, Carrier Dual Beta & Gamma Emitter Intraventricular Catheter (Omaya Reservoir) Convection Enhanced Delivery (CED) C S F and Solid C N S Can cers Administered Dose Absorbed Dose Intrathecal or Direct-to-Tumor Delivery Up to 20x Radiation Dose vs. Standard of Care 2 Delivery Modalities Tumor / ROI Exposure Systemic Exposure
Page 24
Plus Therapeutics, Inc. NASDAQ: PSTV CNS Radiotherapeutic Pipeline 24 Multiple mid-stage trials for unmet medical needs supported by $25M in grants Rhenium ( 186Re) Obisbemeda Indication Trial Design Phase 1 Phase 2 Phase 3 Projected Milestones Leptomeningeal Metastases Single Dose Escalation Completed Dose Optimization Enrolling, data 2026 Recurrent Glioblastoma Single Dose Expansion Enrolling, data 2026 Pediatric Ependymoma & High Grade Glioma Single Dose Escalation Enroll 2026
Page 25
Plus Therapeutics, Inc. NASDAQ: PSTV Pathology of Leptomeningeal Disease and REYOBIQ MOA 25 Rhenium-186 energy profile, delivery modality, path length designed for intrathecal compartmental therapy Cortical Ribbon (Grey) 2.5 mm Linear Met Sub Arachnoid Space (CSF) Nodular and Linear Mets Region of Interest- CSF & Cortical Gray Matter 186Re Radionuclide Avg path length = ~2mm . Macroscopic Microscopic REYOBIQ
Page 26
Plus Therapeutics, Inc. NASDAQ: PSTV ReSPECT-LM Phase 1 Single Dose Escalation Trial 26 Completed: safe delivery very high doses of radiation, no MTD reached + Single outpatient injection + One dose delivers 10x radiation vs 10 doses of fractionated EBRT + Dose escalation • 6.6 to 75 mCi without max dose reached • Recommended Phase 2 Dose (RP2D) 44.1 mCi + Safety & Adverse Events (AE) • Two most common AEs (<20% of patients) – headache & vomiting • Most related AEs either Mild (grade 1, 63%) or Moderate (grade 2, 23%) • 4 patients with Serious Adverse Reactions (SARs); 6 total SARs Minutes Hours
Page 27
Plus Therapeutics, Inc. NASDAQ: PSTV LM Phase 1 Single-Dose Escalation Trial Summary Data 27 Comprehensive clinical response across all measures Patients (Cohorts 1-5) Best Response Following REYOBIQ Single Administration -75% -50% -25% 0% 200% 225% -100% C4 C3 C5 C4 C5 C2 C1 C3 C1 C2 C3 C1 C4 C4 0% C5 Median Overall Survival Clinical Benefit Rate + Circulating tumor cells (CTC) response: 93% (14/15); 5/7 patients w/>80% CTC response survived >1 year + MRI imaging response: 76% (13/17) + Clinical response: 87% (13/15) Median Overall Survival (mOS) + mOS of 9 months, compared to 4-6 months reported + 4 patients remain alive at analysis1 As of Sep 15, 20 25.
Page 28
Plus Therapeutics, Inc. NASDAQ: PSTV LM Clinical Development Plan 28 Establishing RP2D and planning for pivotal trial Completed- Phase 1 Single Dose Safety Trial + No MTD, MFD of 66 mCi + MFD 44.1 mCi + Safety & evidence of clinical benefit at 13.2, 26.4 & 44.1 mCi Completed FDA End of Phase Meeting NOV 2025 Enrolling- Multiple Dose Phase 1/2 Trial + 3 intervals: every 56, 28 & 15 days (13.2 & 26.4 mCi doses only) + 3 doses: 13.2, 26.4 & 44.1 mCi + Phase 2 safety/efficacy expansion at 1 or more doses to plan/power pivotal trial + Assess improvement in overall survival, patient reported outcomes and neurologic improvement over standard of care
Page 29
Plus Therapeutics, Inc. NASDAQ: PSTV FDA Meeting and Feedback 29 FDA ReSPECT-LM end of phase meeting November 2025 Responses to key sponsor enquiries • Accelerated approval- May be appropriate for this indication. • Primary & key endpoints- FDA stated that there are insufficient data to use CTCs as a surrogate endpoint but provided feedback o n additional steps to support validation of CTCs to support future applications. Agency encouraged study of patient reported outcomes, neurologic function as well as overall survival as potential basis of marketing approval. Agency & Sponsor aligned that CTCs could be considered for use as a key secondary endpoint. • Trial design & comparator group- Agency & Sponsor aligned on a randomized controlled design approach. Agency & sponsor further discussed that the study may include an intrathecal chemotherapeutic as a comparator and approaches to standardize the availa ble comparator chemotherapy regimens as well as any background and rescue interventions under the trial protocol in both active a nd control arms. • Treated populations- Agency conveyed that it may be reasonable to incorporate multiple histologies in a single trial, i.e. multi ple underlying etiologies in LM.
Page 30
Plus Therapeutics, Inc. NASDAQ: PSTV Recurrent Glioblastoma 30 Aggressive & deadly disease, resistant to conventional treatments + Most prevalent malignant tumor affecting the brain & CNS2 + Large unmet medical need for GBM patients2 • Poor survival rate (7% at 5 years after diagnosis) • Almost all reoccur after several months post treatment or respond poorly to initial treatment • No standard of care following recurrence, clinical trials recommended • GBM infiltrative margin must be addressed to achieve better outcomes U.S. Annual Incidence 15K1 1. Management es timate 2. Neuro -Oncology, Volume 21 , Issue Supple me nt_5 , October 20 19, Pa ges v1–v10 0, https://doi.org/10.1093 /neuonc/noz150 Infiltrative Margin: 90% of cases recur within 2 cm of original tumor site REYOBIQ Goal: Treat both tumor and infiltrative margin with at least 100 Gy radiation
Page 31
Plus Therapeutics, Inc. NASDAQ: PSTV Advantages vs. External Beam Radiation Therapy 31 Better precision & more radiation delivered than gold standard 30 Doses of EBRT + Maximum Dose ~ 30 Gy + Poor precision 1 Dose of REYOBIQ + Maximum Dose ~ 740 Gy + High precision + High doses to Infiltrative Margin
Page 32
Plus Therapeutics, Inc. NASDAQ: PSTV + Radiation doses to tumor of up to 740 Gy, average doses greater 300 Gy + Clear imaging responses and tumor reduction + Patients receiving >100 Gy had 17 months mOS vs 6 months <100 Gy (p=0.001), note - standard of care is 8 months overall survival + P1 data analyzed against 2 ‘real-world’ control arms: • 38% improvement for the entire population • 113% for patients receiving therapeutic dose radiation (> 100 Gy) ReSPECT-GBM Phase 1 Single Administration Dose Escalation Trial 32 Positive Data published in NATURE Communications
Page 33
Plus Therapeutics, Inc. NASDAQ: PSTV + P2 data analyzed against 2 ‘real-world’ control arms: • 63% improvement in Phase 2 patients (n=15 of 34 planned patients) 1 + 23 (out of 34) patients treated w/RP2D safety profile consistent with Phase 1 data + Survival at interim analysis tracking with P1 data As of November 2023 , n=15. ReSPECT-GBM Phase 2 Single Administration Dose Escalation Trial 33 Interim data in P2 trial shows favorable effect on disease progression & survival
Page 34
Plus Therapeutics, Inc. NASDAQ: PSTV ReSPECT-PBC Phase 1/2 Single Dose Escalation Trial 34 For the treatment of rare, aggressive pediatric brain cancers + Recurrent, refractory, or progressive ependymoma and high-grade glioma + Obtained FDA IND clearance Q2 2025 + Expect to begin enrollment in 1Q 2026 + Initial site: Lurie Children’s Hospital in Chicago, IL + Funded by $3.0 million award from U.S. Department of Defense
Page 35
Plus Therapeutics, Inc. NASDAQ: PSTV REYOBIQ Manufacturing Logistics 35 Scalability in 2026 to meet breadth of clinical and commercial scenarios Overnight Delivery Hospital or Clinic Receives Unit Dose Target and GMP Intermediates Irradiation Services GMP ‘Last Mile’ Unit Dose Production + Manufactured and stored + Institution orders dose one week prior to treatment Drug Ordering + Target irradiated and manufactured under GMP conditions + Drug shipped overnight to arrive in <12 hours + Institution receives unit dose for patient treatment
Page 36
Thank You Contact us at investor@plustherapeutics.com